These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38639831)

  • 1. Dihydropyridine Calcium Channel Blockers and Kidney Outcomes.
    Blum MF; Surapaneni A; Chang A; Inker LA; Chen TK; Appel LJ; Shin JI; Grams ME
    J Gen Intern Med; 2024 Aug; 39(10):1880-1886. PubMed ID: 38639831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials.
    Ku E; Inker LA; Tighiouart H; McCulloch CE; Adingwupu OM; Greene T; Estacio RO; Woodward M; de Zeeuw D; Lewis JB; Hannedouche T; Jafar TH; Imai E; Remuzzi G; Heerspink HJL; Hou FF; Toto RD; Li PK; Sarnak MJ
    Ann Intern Med; 2024 Jul; 177(7):953-963. PubMed ID: 38950402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study.
    Rouette J; McDonald EG; Schuster T; Brophy JM; Azoulay L
    J Am Heart Assoc; 2022 Dec; 11(24):e026789. PubMed ID: 36515246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
    Schroeder EB; Chonchol M; Shetterly SM; Powers JD; Adams JL; Schmittdiel JA; Nichols GA; O'Connor PJ; Steiner JF
    Clin J Am Soc Nephrol; 2018 May; 13(5):727-734. PubMed ID: 29572286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients.
    Satoh M; Hirose T; Satoh H; Nakayama S; Obara T; Murakami T; Muroya T; Asayama K; Kikuya M; Mori T; Imai Y; Ohkubo T; Metoki H
    J Hypertens; 2022 Aug; 40(8):1564-1576. PubMed ID: 35792108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study.
    Tseng YF; Lin HC; Chao JC; Hsu CY; Lin HL
    J Neurol Sci; 2021 May; 424():117412. PubMed ID: 33799214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
    Galceran J; Plana J; Felip A; Pou G; Vila J; Sobrino J
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):751-7. PubMed ID: 20528630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine.
    Tani S; Takahashi A; Nagao K; Hirayama A
    Int Heart J; 2014; 55(6):519-25. PubMed ID: 25310932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.
    Türkmen D; Masoli JAH; Delgado J; Kuo CL; Bowden J; Melzer D; Pilling LC
    Br J Clin Pharmacol; 2023 Feb; 89(2):853-864. PubMed ID: 36134646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line diuretics versus other classes of antihypertensive drugs for hypertension.
    Reinhart M; Puil L; Salzwedel DM; Wright JM
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD008161. PubMed ID: 37439548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study.
    Rouette J; Yin H; McDonald EG; Barkun A; Azoulay L
    Drug Saf; 2022 Jan; 45(1):65-74. PubMed ID: 34714528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.
    Lin SY; Lin CL; Lin CC; Hsu WH; Hsu CY; Kao CH
    Front Pharmacol; 2022; 13():786203. PubMed ID: 35355728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.